<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563432</url>
  </required_header>
  <id_info>
    <org_study_id>TMX-67_BE_I_2011</org_study_id>
    <nct_id>NCT01563432</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic速 in Healthy Volunteers</brief_title>
  <official_title>Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Febuxostat Between TMX-67 40mg 2 Tablets and Feburic速 80mg 1 Tablet in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to compare and evaluate the pharmacokinetic characteristics of
      febuxostat after single oral administration of TMX-67 (test drug) and Feburic速 tablet in
      healthy adults; and to evaluate safety and tolerance following a single-dose administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic characteristics (AUClast and Cmax)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 14, 24 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>febuxostat (TR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>febuxostat (RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Feburic速</intervention_name>
    <description>80 mg*1 tablet</description>
    <arm_group_label>febuxostat (TR)</arm_group_label>
    <arm_group_label>febuxostat (RT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMX-67</intervention_name>
    <description>40 mg*2 tablets</description>
    <arm_group_label>febuxostat (TR)</arm_group_label>
    <arm_group_label>febuxostat (RT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged between 20 and 45 years

          -  Subjects whose weight is 50 kg or more and BMI is between 18 and 29 kg/m2

          -  Subjects who were voluntarily decided to participate in the study and provided written
             informed consent to observe the directions

        Exclusion Criteria:

          -  Medical history which may influence adsorption, distribution, metabolism, excretion of
             the drug

          -  Clinically significant active chronic disease(s)

          -  Persons who are deemed ineligible for the study by the investigator according to the
             clinical laboratory test results or for other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>crossover</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>gout</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

